[Bone mineral density in female patients with systemic lupus erythematosus treated with high glucocorticoid doses].
OBJECTIVE
To study the bone mineral density (BMD) in premenopausal women with systemic lupus erythematosus receiving glucocorticoids (GL) and at 6 months, when the dose of GL was decreased to a level below half of the initial dose.


METHODS
Twelve premenopausal women with SLE were prospectively studied after initiating prednisone therapy at a dose > or = 0.5 mg/kg/day. A densitometric study was performed (Hologic 1000 QDR) of the lumbar spine and femoral neck. Levels of osteocalcine (BGP), catacalcine (PDN-21), testosterone in plasma and saliva, and dehydroepiandrosterone sulphate (DHEAS) were measured. Measurements were repeated after 6 months.


RESULTS
The initial mean dose of prednisone was 40 +/- 10.2 mg/day (0.66 mg/kg/day) with an accumulated dose of 27.6 +/- 23 g. Lumbar and femoral BMD were 1 +/- 0.13 and 0.831 +/- 0.07 g/cm2, respectively. A significant increase was observed in BGP an adrogen levels studied after a 6 months when the dose of GL was decreased to a mean dose of 13.9 +/- 7.5 mg/day (0.23 mg/kg/day), whereas no differences were found in BMD values. In none of the two phases of the study were osteoporosis, correlations between BMD and BGP, between PDN-21 and androgens or with the accumulated or punctual doses of GL documented.


CONCLUSIONS
No decrease in BMD was observed after 6 months of therapy with high doses of GL. In contrast, an increase in BGP and androgenic status was observed when the GL dose was decreased.
Formiga
F
F
Servicio de Medicina Interna, Hospital de Bellvitge-Princeps d'Espanya, CSU de Bellvitge, L'Hospitalet de Llobregat, Barcelona.
Moga
I
I
Navarro
M A
MA
Nolla
J M
JM
Bonnin
R
R
Roig-Escofet
D
D
Pujol
R
R
D000328:Adult; D015519:Bone Density / Q000187:drug effects*; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000378:metabolism; D011241:Prednisone / Q000008:administration & dosage*; D017697:Premenopause; D011446:Prospective Studies
D005938:Glucocorticoids; D011241:Prednisone